Cargando…
Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022
The treatment landscape of chronic lymphocytic leukemia (CLL) has undergone profound change in recent years. Targeted therapies have outnumbered chemotherapy-based treatment approaches demonstrating superior efficacy and tolerability profiles across nearly all CLL patient subgroups in the frontline...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008377/ https://www.ncbi.nlm.nih.gov/pubmed/35437451 http://dx.doi.org/10.1007/s12254-022-00804-x |